Incyte Corp (NASDAQ:INCY)
| 78.48 Delayed Data As of Jan 22 |  -0.17 / -0.22%Today’s Change | 72.00 Today|||52-Week Range 96.79 | -10.12% Year-to-Date |
Latest INCY News | Press Releases
| Incyte Stock Is Down: Buy the Dip? Jan 15 / MotleyFool.com - Paid Partner Content | Will Theravance Biopharma Finally Break Out in 2020? Jan 14 / MotleyFool.com - Paid Partner Content |
| 2 Top Growth Stocks to Buy in January Jan 15 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 78.65 |
| Today’s open | 78.83 |
| Day’s range | 78.22 - 79.53 |
| Volume | 845,417 |
| Average volume (3 months) | 1,322,294 |
| Market cap | $17.3B |
Data as of 4:00pm ET, 01/22/2020
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | +269.07% |
| Earnings growth (next 5 years) | +30.50% |
| Revenue growth (last year) | +22.50% |
| P/E ratio | 42.0 |
| Price/Sales | 7.29 |
| Price/Book | 8.91 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| SGENSeattle Genetics Inc | +3.03 | +2.79% |
| GLPGGalapagos NV | -3.18 | -1.33% |
| ALNYAlnylam Pharmaceutic... | -2.35 | -1.99% |
| MYLMylan NV | +0.14 | +0.65% |
Data as of 4:00pm ET, 01/22/2020
Financials
| Next reporting date | February 14, 2020 |
| EPS forecast (this quarter) | $0.35 |
| Annual revenue (last year) | $1.9B |
| Annual profit (last year) | $109.5M |
| Net profit margin | 5.82% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Wilmington, Delaware |
Forecasts
